Evidence map›Paper›PMID 26179371›Full record

ArticleScientific reports2015

Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes.

Samantha Morley, Sungyong You, Sara Pollan, Jiyoung Choi, Bo Zhou, Martin H Hager, Kenneth Steadman, Cristiana Spinelli, Kavitha Rajendran, Arkadiusz Gertych and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. DIAPH3 predicts survival of patients withFrontiers in oncology · 2024
    Article
  4. Role of actin-binding proteins in prostate cancer.Frontiers in cell and developmental biology · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. TIP5 primes prostate luminal cells for the oncogenic transformation mediated byProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Samantha Morley1] Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048 [2] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [3] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Sungyong YouDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Sara PollanDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Jiyoung ChoiUrological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115.
Bo ZhouDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Martin H Hager1] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [2] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Kenneth SteadmanDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Cristiana SpinelliDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Kavitha RajendranDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115.
Arkadiusz GertychDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Jayoung Kim1] Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048 [2] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [3] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Rosalyn M Adam1] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [2] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Wei YangDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Ramaswamy KrishnanDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115.
Beatrice S KnudsenDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
Dolores Di Vizio1] Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048 [2] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [3] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Michael R Freeman1] Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048 [2] Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115 [3] Department of Surgery, Harvard Medical School, Boston, MA 02115.
Cedars-Sinai Medical Center · USBoston Children's Hospital · USBeth Israel Deaconess Medical Center · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Urethral Tissue BioengineeringP50DK065298 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ADAM, ROSALYN M · 2003 to 2012
$9.8M
Amoeboid Membrane Dynamics in Prostate CancerR01CA143777 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R · 2010 to 2014
$1.7M
Fatty Acid Synthase, Caveolin-1 and Membrane Microdomains in Prostate CancerR00CA131472 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DI VIZIO, DOLORES · 2010 to 2012
$722k
Urinary Metabolites in IC PBS DiagnosisR01DK100974 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI ANGER, JENNIFER TASH, KIM, JAYOUNG · 2013 to 2013
$416k
NCI NIH HHS P50 CA092131NCI NIH HHS P50CA092131NCI NIH HHS R00 CA131472NCI NIH HHS R01 CA143777NIDDK NIH HHS 1R01DK100974NIDDK NIH HHS P50 DK065298NIDDK NIH HHS P50 DK65298NIDDK NIH HHS R01 DK100974
6 · The paper itself

Abstract

Taxanes are widely employed chemotherapies for patients with metastatic prostate and breast cancer. Here, we show that loss of Diaphanous-related formin-3 (DIAPH3), frequently associated with metastatic breast and prostate cancers, correlates with increased sensitivity to taxanes. DIAPH3 interacted with microtubules (MT), and its loss altered several parameters of MT dynamics as well as decreased polarized force generation, contractility, and response to substrate stiffness. Silencing of DIAPH3 increased the cytotoxic response to taxanes in prostate and breast cancer cell lines. Analysis of drug activity for tubulin-targeted agents in the NCI-60 cell line panel revealed a uniform positive correlation between reduced DIAPH3 expression and drug sensitivity. Low DIAPH3 expression correlated with improved relapse-free survival in breast cancer patients treated with chemotherapeutic regimens containing taxanes. Our results suggest that inhibition of MT stability arising from DIAPH3 downregulation enhances susceptibility to MT poisons, and that the DIAPH3 network potentially reports taxane sensitivity in human tumors.

Indexed as

Adaptor Proteins, Signal TransducingBreast NeoplasmsEpothilonesFemaleForminsGene SilencingHumansMaleMicrotubulesProstatic NeoplasmsTaxoidsAdaptor Proteins, Signal TransducingDIAPH3 protein, humanepothilone BEpothilonesForminsTaxoids

Identifiers

PMID26179371
PMCPMC4503992
OpenAlexW2159510040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.